Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Feb 06, 2026
Banco Santander vs. Bank of America: Earnings Preview as Global Banking Momentum Faces a Reality Check

Banco Santander vs. Bank of America: Earnings Preview as Global Banking Momentum Faces a Reality Check

Key Takeaways

  • Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.

  • Consensus calls for Q4 EPS of $0.25, as Santander works toward ~€62 billion in 2025 revenue and ~16.5% RoTE post-AT1.

  • Bank of America (BAC) recently posted Q4 2025 net income of $7.6 billion (EPS $0.98, a beat), with full-year revenue up 7% to $113 billion.

  • Santander’s globally diversified footprint contrasts with BAC’s U.S.-centric scale, though both banks are showing resilient net interest income amid rate normalization.

  • Santander targets 13% CET1 and up to €10 billion in share buybacks, while BAC guides for 5–7% net interest income growth in 2026.

  • Investor focus centers on Santander’s execution against full-year targets versus Bank of America’s post-earnings momentum and efficiency gains.

Why This Comparison Matters

Banco Santander’s Q4 earnings will cap a standout year, highlighted by record profits, expanding customer numbers, and solid fee growth across regions. As one of the most globally diversified large banks—with meaningful exposure to Europe and Latin America—Santander’s results will test earnings durability amid currency volatility and a shifting rate backdrop.

Bank of America offers a counterpoint. Fresh off a Q4 earnings beat, BAC exemplifies U.S. banking strength, supported by scale in consumer banking, wealth management, and capital markets. Together, the two institutions illustrate the trade-off investors face between international growth optionality and U.S. stability as global banking momentum meets a more normalized environment.

Banco Santander: Earnings in Focus

Santander is expected to report Q4 EPS of $0.25, up from $0.21 a year earlier. Management has reaffirmed its 2025 targets, including:

  • ~€62 billion in revenue

  • Mid- to high-single-digit fee growth

  • Lower operating costs in euro terms

  • Cost of risk around 1.15%

  • RoTE above 17% (approximately 16.5% post-AT1)

  • CET1 ratio of 13%

In Q3, Santander delivered a record €3.5 billion profit, with nine-month revenue of €46.3 billion and fees up 4%. Key areas to watch in Q4 include seasonal fee trends, net interest income stability excluding Argentina, and cost efficiencies from the ONE Transformation program. Historically, Santander has modestly beaten expectations, with shares often reacting 2–5% on positive surprises. Capital returns remain a highlight, with €10 billion in buybacks planned for 2025–2026.

Bank of America: Recent Results and Outlook

Bank of America reported Q4 2025 results on January 14, 2026, posting $7.6 billion in net income, up 12% year over year, and EPS of $0.98, ahead of consensus. Revenue rose 7% to roughly $28.5 billion, supported by stronger net interest income and solid trading performance.

For the full year, BAC generated $30.5 billion in net income, with EPS of $3.81, reflecting double-digit growth. Net interest income rose 10% in Q4, and average deposits remained strong at $2.01 trillion. Management guided to 5–7% NII growth in 2026, mid-single-digit loan growth, and approximately 200 basis points of operating leverage, supported by a CET1 ratio of 11.4%. Despite the earnings beat, shares initially dipped as investors rotated within the financial sector.

AI Trading Perspective

From a technical standpoint, Trend Trader for Beginners Strategy for Large-Cap Stocks (60-min TA) highlights Bank of America as a candidate for momentum-based trading. The strategy uses 60-minute technical analysis to identify trend signals in large-cap stocks, aiming to capture earnings-driven and macro-driven moves while managing downside risk—particularly relevant in a consolidating banking sector.

Head-to-Head Snapshot

Santander’s nine-month profit trajectory suggests potential €13–14 billion full-year earnings, supporting its targeted returns. Bank of America, however, operates at far greater absolute scale, with $30.5 billion in FY net income.

  • Growth drivers: Santander’s fee expansion, digital adoption, and Latin America exposure versus BAC’s net interest income, wealth management, and trading strength.

  • Risks: FX volatility and emerging-market sensitivity for Santander; deposit costs and U.S. economic slowdown risk for BAC.

  • Capital strength: Santander’s ~13% CET1 enables aggressive buybacks, while BAC’s efficiency gains and operating leverage underpin shareholder returns.

Market sentiment currently favors U.S.-focused banks amid global uncertainty, though Santander’s diversification offers upside if currency and rate headwinds stabilize.

Tickeron AI Verdict

Tickeron’s AI models presently lean toward Bank of America, citing higher earnings visibility, recent execution strength, and a supportive U.S. macro backdrop heading into 2026. Santander remains attractive for investors seeking growth and capital return potential, but foreign-exchange exposure and regional volatility reduce near-term certainty. In this pairing, BAC offers stability, while SAN provides selective upside tied to global recovery trends.

Disclaimers and Limitations

Related Ticker: SAN, BAC

Momentum Indicator for SAN turns positive, indicating new upward trend

SAN saw its Momentum Indicator move above the 0 level on July 30, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 88 similar instances where the indicator turned positive. In of the 88 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for SAN just turned positive on July 31, 2026. Looking at past instances where SAN's MACD turned positive, the stock continued to rise in of 49 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SAN advanced for three days, in of 314 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 360 cases where SAN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for SAN moved out of overbought territory on July 08, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 53 similar instances where the indicator moved out of overbought territory. In of the 53 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SAN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

SAN broke above its upper Bollinger Band on August 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 20, placing this stock better than average.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. SAN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.662) is normal, around the industry mean (1.938). P/E Ratio (14.390) is within average values for comparable stocks, (16.226). SAN's Projected Growth (PEG Ratio) (4.064) is very high in comparison to the industry average of (1.631). Dividend Yield (0.019) settles around the average of (0.025) among similar stocks. P/S Ratio (3.026) is also within normal values, averaging (4.327).

Notable companies

The most notable companies in this group are JPMorgan Chase & Co (NYSE:JPM), Bank of America Corp (NYSE:BAC), HSBC Holdings PLC (NYSE:HSBC), Wells Fargo & Co (NYSE:WFC), Citigroup (NYSE:C), Barclays PLC (NYSE:BCS).

Industry description

Major banks are among the biggest companies in the world, often times with global reach and market capitalizations in the multi-billions. Large banks often have multiple arms spanning different disciplines, from deposits, to investment banking, to wealth management and insurance. The biggest banks often have key competitive advantages over smaller players in the industry in terms of brand recognition, cost of capital, and efficiency. Think J.P. Morgan, Bank of America, Wells Fargo, and Citigroup.

Market Cap

The average market capitalization across the Major Banks Industry is 216.86B. The market cap for tickers in the group ranges from 1.04M to 954.93B. JPM holds the highest valuation in this group at 954.93B. The lowest valued company is BACRP at 1.04M.

High and low price notable news

The average weekly price growth across all stocks in the Major Banks Industry was 4%. For the same Industry, the average monthly price growth was 3%, and the average quarterly price growth was 18%. ING experienced the highest price growth at 6%, while SMFG experienced the biggest fall at -3%.

Volume

The average weekly volume growth across all stocks in the Major Banks Industry was 3%. For the same stocks of the Industry, the average monthly volume growth was 3% and the average quarterly volume growth was -35%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 67
P/E Growth Rating: 30
Price Growth Rating: 39
SMR Rating: 8
Profit Risk Rating: 19
Seasonality Score: -22 (-100 ... +100)
View a ticker or compare two or three
SAN
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a major bank

Industry MajorBanks

Profile
Details
Industry
Major Banks
Address
Avenida de Cantabria s/n
Phone
+34 912893280
Employees
212764
Web
https://www.santander.com
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.